Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0W7VG
|
||||
| Former ID |
DCL000423
|
||||
| Drug Name |
AMG 108
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Discontinued in Phase 2 | [1] | ||
| Company |
Amgen
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C11H14N4O4
|
||||
| Canonical SMILES |
C1=C(C2=C(N1)C(=O)N=CN2)C3C(C(C(N3)CO)O)O
|
||||
| InChI |
1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1
|
||||
| InChIKey |
IWKXDMQDITUYRK-KUBHLMPHSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
820339, 824927, 829471, 854455, 854458, 7888374, 11532495, 14774821, 15392822, 24770619, 24770621, 24770665, 36887500, 46391523, 46391948, 46392657, 46394112, 46394113, 46530883, 47208247, 49689710, 57404625, 77434485, 85856193, 103500429, 104077585, 104632275, 117682608, 134338803, 134339052, 134340118, 135020342, 135675084, 137042995, 141755560, 144080329, 160644592, 160779316, 165245606, 180372225, 186024301, 198952847, 224718993, 226820362, 241051921, 243906436, 252166484
|
||||
| ChEBI ID |
ChEBI:43362
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-1 receptor, type II | Target Info | Antagonist | [2], [3] | |
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| Hematopoietic cell lineage | |||||
| Amoebiasis | |||||
| HTLV-I infection | |||||
| Transcriptional misregulation in cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | |||||
| Pathway Interaction Database | IL1-mediated signaling events | ||||
| Reactome | Interleukin-1 signaling | ||||
| WikiPathways | MAPK Signaling Pathway | ||||
| Interleukin-1 signaling | |||||
| Apoptosis Modulation and Signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020487) | ||||
| REF 2 | Inflammatory molecules: a target for treatment of systemic autoimmune diseases. Autoimmun Rev. 2007 Nov;7(1):1-7. Epub 2007 Mar 26. | ||||
| REF 3 | Clinical pipeline report, company report or official report of Amgen (2009). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.